Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

European Journal of Pharmacology

Volumn 590, Issue 1-3, 2008, Pages 400-408

  Oku, Hisashi ^a   Shimizu, Toshikatsu ^a   Kawabata, Tomoji ^a   Nagira, Morio ^a   Hikita, Ichiro ^a   Ueyama, Azumi ^a   Matsushima, Shuuichi ^a   Torii, Mikinori ^a   Arimura, Akinori ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Basic fibroblast growth factor; Interferon ; Pirfenidone; Prednisolone; Pulmonary fibrosis; Transforming growth factor 1

Indexed keywords

ANTIFIBROTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PIRFENIDONE; PREDNISOLONE; S 7701; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; LUNG EDEMA; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TREATMENT RESPONSE;

ANIMALS; BLEOMYCIN; CHEMOKINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 2; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE II; INTERLEUKIN-12 SUBUNIT P40; LUNG; MALE; MICE; MICE, INBRED ICR; PREDNISOLONE; PULMONARY FIBROSIS; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48149113955     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.046     Document Type: Article

References (59)

1. Aggarwal A.N., and Behera D. Interferon-γ1b: impact of new indications (idiopathic pulmonary fibrosis). Expert Opin. Pharmacother 7 (2000) 1423-1427
2. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment: International Consensus Statement: American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161 (2000) 646-664
3. Antoniades H.N., Bravo M.A., Avila R.E., Galanopoulos T., Neville-Golden J., Maxwell M., and Selman M. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J. Clin. Invest. 86 (1990) 1055-1064
4. Arai T., Abe K., Matsuoka H., Yoshida M., Mori M., Goya S., Kida H., Nishino K., Osaki T., Tachibana I., Kaneda Y., and Hayashi S. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am. J. Physiol., Lung Cell Mol. Physiol. 278 (2000) L914-L922
5. Ashcroft T., Simpson J.M., and Timberbell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41 (1988) 467-470
6. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., Taguchi Y., Nagai S., Itoh H., Ohi M., Sato A., Kudoh S., and Raghu G. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171 (2005) 1040-1047
7. Bruss M.L., Margolin S.B., and Giri S.N. Pharmacokinetics of orally administered pirfenidone in male and female beagles. J. Vet. Pharmacol. Ther. 27 (2004) 361-367
8. Chaudhary N.V., Schnapp A., and Park J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 173 (2006) 769-776
9. Collard H.R., and King Jr. T.E. Demystifying idiopathic interstitial pneumonia. Arch. Intern. Med. 163 (2003) 17-29
10. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 77 (1991) 1627-1652
11. Ekimoto H., Takahashi K., Matsuda A., and Umezawa H. Animal models on bleomycin-induced pulmonary fibrosis - comparison of the systemic (intraperitoneal) administration with the local (intratracheal) instillation. Jpn. J. Cancer Chemother. 10 (1983) 2550-2557
12. Ekimoto H., Takahashi K., Matsuda A., and Umezawa H. Changes of anticancer activity and pulmonary toxicity of bleomycins in differences of administration schedules and routes in mice. Jpn. J. Cancer Chemother. 11 (1984) 853-857
13. Ekimoto H., Takada K., Ohnuki T., Takahashi K., Matsuda A., Takita T., and Umezawa H. Different sensitivity to bleomycin-induced pulmonary fibrosis among various strains of mice. J. Clin. Biochem. Nutr. 2 (1987) 25-31
14. Entzian P., Zahringer U., Schlaak M., Gerlach C., Galle J., and Zabel P. Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis. Int. J. Immunopharmacol. 20 (1998) 723-735
15. Gross T.J., and Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345 (2001) 517-525
16. Gurujeyalakshmi G., and Giri S.N. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-β and procollagen I and III gene expression. Exp. Lung Res. 21 (1995) 791-808
17. Gurujeyalakshmi G., Hollinger M.A., and Giri S.N. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol. 276 (1999) L311-318
18. Hashimoto N., Jin H., Liu T., Chensue S.W., and Phan S.H. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 113 (2004) 243-252
19. Heinzel F.P., Hujer A.M., Ahmed F.N., and Rerko R.M. In vivo production and function of IL-12 p40 homodimers. J. Immunol. 158 (1997) 4381-4388
20. Hirano T. Interleukin 6. In: Thomson A.W. (Ed). The Cytokine Handbook (1991), Academic Press, London 169-190
21. Hosoya T. Steroid resistance and lung-tissue cytokines in experimental bleomycin-induced lung fibrosis. Nippon Kyoubu Shikkann Gakkai Zasshi 35 (1997) 766-775
22. Huaux F., Arras M., Tomasi D., Barbarin V., Delos M., Coutelier J.P., Vink A., Phan S.H., Renauld J.C., and Lison D. A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J. Immunol. 169 (2002) 2653-2661
23. Inoue Y., King T.E.J., Tinkle S.S., Dockstader K., and Newman L.S. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am. J. Pathol. 149 (1996) 2037-2054
24. Inoue Y., King Jr. T.E., Barker E., Daniloff E., and Newman L.S. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 166 (2002) 765-773
25. Iyer S.N., Wild J.S., Schiedt M.J., Hyde D.M., Margolin S.B., and Giri S.N. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125 (1995) 779-785
26. Iyer S.N., Gurujeyalakshmi G., and Giri S.N. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 289 (1999) 211-218
27. Iyer S.N., Gurujeyalakshmi G., and Giri S.N. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291 (1999) 367-373
28. Iyer S.N., Hyde D.M., and Giri S.N. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 24 (2000) 477-491
29. Kakugawa T., Mukae H., Hayashi T., Ishii H., Abe K., Fujii T., Oku H., Miyazaki M., Kadota J., and Kohno S. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur. Respir. J. 24 (2004) 57-65
30. Kehrer J.P., and Margolin S.B. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol. Lett. 90 (1997) 125-132
31. Khalil N., Whitman C., Zuo L., Danielpour D., and Greenberg A. Regulation of alveolar macrophage transforming growth factor-β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in rat. J. Clin. Invest. 92 (1993) 1812-1818
32. Kitasato Y., Hoshino T., Okamoto M., Kato S., Koda Y., Nagata N., Kinoshita M., Koga H., Yoon D.-Y., Asao H., Ohmoto H., Koga T., Rikimaru T., and Aizawa H. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 31 (2004) 619-625
33. Kondoh Y., Taniguchi H., Kawabata Y., Yokoi T., Suzuki K., and Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 (1993) 1808-1812
34. Laxer U., Lossons I.S., Gillis S., Or R., Christensen T.G., Goldstein R.H., and Breuer R. The effect of enoxaparin on bleomycin-induced lung injury in mice. Exp. Lung Res. 25 (1999) 531-541
35. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., Shipley J.M., Gotwals P., Noble P., Chen Q., Senior R.M., and Elias J.A. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J. Exp. Med. 194 (2001) 809-821
36. Lesur O.J., Mancini N.M., Humbert J.C., Chabot F., and Polu J.M. Interleukin-6, interferon-gamma and phospholipid levels in the alveolar lining fluid of human lung. Profiles in coal worker's pneumoconiosis and idiopathic pulmonary fibrosis. Chest 106 (1994) 407-413
37. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-270
38. Luo Y., Laning J., Hayashi M., Hancock P.R., Rollins B., and Dorf M.E. Serologic analysis of the mouse beta chemokine JE/monocyte chemoattractant protein-1. J. Immunol. 153 (1994) 3708-3716
39. Margolin S.B., and Lefkowitz S. Pirfenidone: a novel pharmacologic agent for prevention and resolution of lung fibrosis. FASEB J. 8 (1994) A382
40. Margolin S., Margolin B., and Margolin D. Removal of interstitial pulmonary fibrosis (asbestos-induced) by oral chemotherapy with pirfenidone. Fed. Proc. 41 (1982) 1550
41. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol. Med. 117 (2005) 69-80
42. Misra H.P., and Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. 204 (2000) 119-126
43. Nagai S., Hamada K., Shigematsu M., Taniyama M., Yamauchi S., and Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 41 (2002) 1118-1123
44. Nakanishi K., Toshimoto T., Tsutsui H., and Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19 (2001) 423-474
45. Oku H., Nakazato H., Horikawa T., Tsuruta Y., and Suzuki R. Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. 446 (2002) 167-176
46. Phan S.H., and Kunkel S.L. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp. Lung Res. 18 (1992) 29-43
47. Piguet P.F., Collart M.A., Grau G.E., Kapanci Y., and Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 170 (1989) 655-663
48. Raghu G., Johnson W.C., Lockhart D., and Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159 (1999) 1061-1069
49. Raghu G., Brown K.K., Bradford W.Z., Starko K., Noble P.W., Schwartz D.A., and King T.E. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350 (2004) 125-133
50. Saito A., Okazaki H., Sugawara I., Yamamoto K., and Takizawa H. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int. Arch. Allergy Immunol. 132 (2003) 168-176
51. Selman M., King Jr. T.E., and Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134 (2001) 136-151
52. Staub N.C. Pulmonary edema. Physiol. Rev. 54 (1974) 678-811
53. Tamagawa K., Taooka Y., Maeda A., Hiyama K., Ishioka S., and Yamakido M. Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 161 (2000) 1279-1284
54. Warwick M.T., Burrows B., and Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 35 (1980) 593-599
55. White E.S., Lazar M.H., and Thannickal V.J. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J. Pathol. 201 (2003) 343-354
56. Woessner J.F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93 (1961) 440-447
57. Yang G., Volk A., Petley T., Emmell E., Giles-Komar J., Shang X., Li J., Das A.M., Shealy D., Griswold D.E., and Li L. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28 (2004) 224-232
58. Ziesche R., and Block L.H. Mechanisms of antifibrotic action of interferon gamma-1b in pulmonary fibrosis. Wien Klin. Wochenschr. 112 (2000) 785-790
59. Ziesche R., Hofbauer E., Wittmann K., Petkov V., and Block L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341 (1999) 1264-1269